Dataset Information

Statement on the safety of d-ribose.

ABSTRACT: In 2018, the EFSA NDA Panel adopted the Scientific Opinion on the safety of d-ribose as a novel food pursuant to Regulation (EU) 2015/2283 when used in a variety of food, concluding that d-ribose is safe for the general population at intake levels up to 36 mg/kg body weight (bw) per day, but that its safety at the intended uses and use levels as proposed by the applicant could not be established. Following a request from the European Commission, the EFSA NDA Panel was asked to carry out a supplementary safety assessment for d-ribose by considering the new proposed uses and use levels submitted by the applicant. In order to address the present mandate, an intake assessment was carried out based on individual data from the EFSA Comprehensive European Food Consumption Database. Intakes were estimated for all age groups of the general population. The resulting ranges for the mean and high-level estimated intakes of d-ribose for all the population groups, including the target population groups, did not exceed the acceptable level of intake for the general population previously defined, i.e. 36 mg/kg bw per day, except for one survey on adolescents where the mean and 95th percentile of the intake estimates were 8.6 and 39.4 mg/kg bw per day, respectively. The Panel concludes that the novel food, d-ribose, is safe under the new proposed conditions of use.

SUBMITTER: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA)

PROVIDER: S-EPMC7009567 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Statement on the safety of d-ribose.

Turck Dominique D Castenmiller Jacqueline J De Henauw Stefaan S Hirsch-Ernst Karen Ildico KI Kearney John J Knutsen Helle Katrine HK Maciuk Alexandre A Mangelsdorf Inge I McArdle Harry J HJ Naska Androniki A Pelaez Carmen C Pentieva Kristina K Siani Alfonso A Thies Frank F Tsabouri Sophia S Vinceti Marco M Dean Tara T Engel Karl Heinz KH Heinonen Marina M Marchelli Rosangela R Neuhäuser-Berthold Monika M Poulsen Morten M Pöting Annette A Sanz Yolanda Y Schlatter Josef Rudolf JR Germini Andrea A van Loveren Henk H

EFSA journal. European Food Safety Authority 20181213 12

In 2018, the EFSA NDA Panel adopted the Scientific Opinion on the safety of d-ribose as a novel food pursuant to Regulation (EU) 2015/2283 when used in a variety of food, concluding that d-ribose is safe for the general population at intake levels up to 36 mg/kg body weight (bw) per day, but that its safety at the intended uses and use levels as proposed by the applicant could not be established. Following a request from the European Commission, the EFSA NDA Panel was asked to carry out a supple ...[more]

PMID: 32625778

Similar Datasets

Project description:IntroductionCoronavirus disease 2019 (COVID-19) is a contagious disease that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Health care workers are at risk of infection from aerosolisation of respiratory secretions, droplet and contact spread. There are a number of procedures that represent a high risk of aerosol generation during cardiothoracic surgery. It is important that adequate training, equipment and procedures are in place to reduce that risk.RecommendationsWe provide a number of key recommendations, which reduce the risk of aerosol generation during cardiothoracic surgery and help protect patients and staff. These include general measures such as patient risk stratification, appropriate use of personal protective equipment, consideration to delay surgery in positive patients, and careful attention to theatre planning and preparation. There are also recommended procedural interventions during airway management, transoesophageal echocardiography, cardiopulmonary bypass, chest drain management and specific cardiothoracic surgical procedures. Controversies exist regarding the management of low risk patients undergoing procedures at high risk of aerosol generation, and recommendations for these patients will change depending on the regional prevalence, risk of community transmission and the potential for asymptomatic patients attending for these procedures.Changes in management as a result of this statementThis statement reflects changes in management based on expert opinion, national guidelines and available evidence. Our knowledge with regard to COVID-19 continues to evolve and with this, guidance may change and develop. Our colleagues are urged to follow national guidelines and institutional recommendations regarding best practices to protect their patients and themselves.Endorsed byAustralian and New Zealand Society of Cardiac and Thoracic Surgeons and the Anaesthetic Continuing Education Cardiac Thoracic Vascular and Perfusion Special Interest Group.

Dataset Information

Statement on the safety of d-ribose.

Publications

Statement on the safety of d-ribose.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets